25 août 2022

FDA accorde la désignation de traitement révolutionnaire au talquetamab pour le myélome récidivant/réfractaire

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.

Lire la suite ici.